At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 130 enrolled
Drug / intervention
SOF/VELdrug
Likely dose
SOF/VEL 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection
In Brief
A Phase 3 clinical trial evaluating SOF/VEL for Hepatitis C Virus Infection. Completed, enrolled 130 participants across 16 sites.
Detailed Summary
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) fixed-dose combination (FDC) for 12 weeks in adults with chronic hepatitis C virus (HCV) infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C Virus Infection
CountriesIndia
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartMar 2017
Primary CompletionFeb 2018
TodayJul 2026
First PostedMar 8, 2017
Enrollment StartMar 23, 2017
Primary CompletionFeb 7, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.3 years ago
Interventions
SOF/VELdrug
400/100 mg FDC tablet(s) administered orally once daily